CSF2 and cancer: To examine the effect of L-pampoTM on the migration of DCs into the lymph nodes, we formulated OVA257–264 peptides with various adjuvants, including L-pampoTM and Montanide ISA 51 or GM-CSF, which are used in clinical trials of cancer peptide vaccines [15].